New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 30, 2014
09:04 EDTRNA, SRPTFDA says 'willing to explore' accelerated approval for DMD drugs
In response to a White House petition urging the FDA to accelerate approval for safe, effective therapies for children with Duchenne, Janet Woodcock, Director, FDA Center for Drug Evaluation and Research, said in a response, "We are willing to explore the use of all potential pathways for the approval of drugs for Duchenne muscular dystrophy, including accelerated approval, as appropriate." She added, "We share your sense of urgency to make safe and effective drugs available for patients with Duchenne muscular dystrophy as soon as possible. That's why we're actively engaged with a number of drug companies focused on developing new drugs for Duchenne muscular dystrophy, including Sarepta Therapeutics, the company developing eteplirsen, an investigational new drug for Duchenne muscular dystrophy." Shares of Sarepta (SRPT) are trading up 5%, or 97c, to $21.30 in pre-market trading. Yesterday afternoon, Wall Street Journal reported that Sarepta is limiting the role its CEO Chris Garabedian is playing in talks with the FDA. Prosensa (RNA) is also developing a treatment for Duchenne muscular dystroph, or DMD. Reference Link
News For SRPT;RNA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2015
10:32 EDTSRPTOptions with increasing implied volatility
Subscribe for More Information
10:13 EDTSRPTOptions with increasing implied volatility
Options with increasing implied volatility: ESPR SRPT CX RAX YY SPLK QIHU HFC OWW BBY
July 29, 2015
06:38 EDTSRPTBioMarin price target raised to $163 from $147 at Piper Jaffray
Subscribe for More Information
July 28, 2015
10:38 EDTSRPTOptions with increasing implied volatility
Subscribe for More Information
July 27, 2015
10:40 EDTSRPTIsis 'most obvious' Biogen takeover target, TheStreet's Feuerstein says
Subscribe for More Information
July 22, 2015
17:06 EDTSRPTSarepta announce publication of Phase I clinical data of AVI-7288
Subscribe for More Information
July 20, 2015
14:32 EDTSRPTFDA panel likely to review Sarepta, BioMarin drugs in November, TheStreet says
Subscribe for More Information
11:03 EDTSRPTSarepta rises after Roth says added data can keep it ahead of BioMarin
Subscribe for More Information
10:13 EDTSRPTOptions with decreasing implied volatility
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use